Author

Kori Wallace 1

1 AbbVie Inc.,North Chicago,United States

52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION

Geert R. D'Haens, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Peter Bossuyt, Silvio Danese, Ezequiel Neimark, Alexandra Song, Xiaomei Liao, Kori Wallace, Javier Zambrano, Rachel Duan, Kristina Kligys, Marla C. Dubinsky

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens, Brian Feagan, William J. Sandborn, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Marc Ferrante, Ezequiel Neimark, Peter Bossuyt, Silvio Danese, Alexandra Song, Xiaomei Liao, Tian Feng, Rachel Duan, Sofie Berg, Jean-Frédéric Colombel, Kori Wallace

Early symptom improvement with risankizumab treatment in patients with moderately to severely active Crohn's disease: analysis from a Phase 2 study

Brian G. Feagan, William Sandborn, Geert R. D'Haens, Julian Panés, Arthur Kaser, Marc Ferrante, Edouard Louis, Olivier Dewit, Ursula Seidler, Kyung-Jo Kim, Kristina Kligys, Kori Wallace, Xiaomei Liao, Wan-Ju Lee, Markus F. Neurath

EFFICACY AND SAFETY OF OPEN-LABEL MAINTENANCE THERAPY WITH SUBCUTANEOUS RISANKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE

Brian G. Feagan, Julian Panés, Marc Ferrante, Arthur Kaser, Geert R. D'Haens, William Sandborn, Edouard Louis, Markus Friedrich Neurath, Denis Franchimont, Olivier Dewit, Ursula Seidler, Kyung-Jo Kim, Christian Selinger, Steven J Padula, Ivona Herichova, Anne M. Robinson, Kori Wallace, Jun Zhao, Adina Soaita, Sudha Visva

Long-term effect of risankizumab on improved and sustained health-related quality of life over 3 years in patients with moderate to severe Crohn's disease: interim analysis of a phase 2 open-label extension study

Edouard Louis, Peter Bossuyt, Julian Panés, Brian G. Feagan, Jasmina Kalabic, Kori Wallace, Naijun Chen, Wan-Ju Lee, Marc Ferrante

Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: 3-year interim results from the ongoing Phase 2 open-label extension study

Marc Ferrante, Brian G. Feagan, Julian Panés, Filip Baert, Edouard Louis, Olivier Dewit, Arthur Kaser, Weijiang Rachel Duan, Dawn Gustafson, Xiaomei Liao, Kori Wallace, Jasmina Kalabic, Geert R. D'Haens

LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: INTERIM RESULTS OF THE ONGOING PHASE 2 OPEN-LABEL EXTENSION STUDY

Marc Ferrante, Julian Panés, Filip Baert, Edouard Louis, Arthur Kaser, Dawn Gustafson, David Hall, Wulf O. Böcher, Ivona Herichova, Xiaomei Liao, Kori Wallace, Jasmina Kalabic, Geert R. D'Haens

OPERATING PROPERTIES OF DIFFERENT PATIENT REPORTED OUTCOME ENDPOINTS COMBINED WITH ENDOSCOPIC EVALUATION: DATA FROM EXTEND

Brian G. Feagan, William Sandborn, Paul Rutgeerts, Barrett G. Levesque, Reena Khanna, Anne M. Robinson, Bidan Huang, Qian Zhou, Holly A. read, Kori Wallace, Ana Paula Machado De Lacerda, Roopal B Thakkar

RISANKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE WHO FAILED 1 VS > 1 PRIOR BIOLOGIC TREATMENT: RESULTS FROM THE MOTIVATE STUDY

Remo Panaccione, Stefan Schreiber, Laurent Peyrin-Biroulet, Edward V. Loftus, Marla C. Dubinsky, Marc Ferrante, Alexandra Song, Bidan Huang, Xiaomei Liao, Sofie Berg, Rachel Duan, Kori Wallace, Brian Feagan

Item 1 - 10 / 11
1
2